Related Experiment Video
Updated: Jun 5, 2026
09:00
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
Published on: April 18, 2025
Proteomics in pancreatic cancer research
Daniela Cecconi1, Marta Palmieri, Massimo Donadelli
1Department of Biotechnology, University of Verona, Verona, Italy. daniela.cecconi@univr.it
Proteomics
|January 14, 2011
Summary
Proteomic technologies are crucial for understanding pancreatic cancer (PC). This review highlights key protein biomarkers identified in tissues, body fluids, and cell lines for early diagnosis, metastasis, and treatment strategies.
Area of Science:
- Proteomics
- Oncology
- Biochemistry
Background:
- Pancreatic cancer (PC) remains a significant health challenge with limited early diagnostic markers.
- Proteomic technologies offer powerful tools to unravel the complex molecular landscape of PC.
Purpose of the Study:
- To provide a comprehensive overview of the role of proteomic technologies in pancreatic cancer research.
- To identify and discuss candidate biomarkers for early diagnosis, metastasis, and therapeutic targeting in PC.
Main Methods:
- Analysis of proteomic data from various sample origins: pancreatic cancer tissues, body fluids (serum, plasma, pancreatic juice), and cell lines.
- Review of established techniques like 2-DE and advanced high-throughput proteomic strategies.
Main Results:
- Identification of candidate biomarkers in precursor lesions for early PC diagnosis.
- Characterization of proteins involved in cytoskeleton modifications, hypoxia, invasion, metastasis, and tumor-stroma interactions.
- Discovery of novel biomarkers in patient biofluids and insights into drug resistance mechanisms in cell line models.
Conclusions:
- Proteomics plays a vital role in advancing pancreatic cancer research, from early detection to understanding treatment response.
- Continued development of proteomic strategies is essential for overcoming current limitations and improving patient outcomes.
